Equities researchers at StockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Free Report) in a report released on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Calithera Biosciences Stock Performance
CALA opened at $0.03 on Friday. The company has a fifty day moving average price of $0.03 and a 200-day moving average price of $0.04. Calithera Biosciences has a one year low of $0.01 and a one year high of $0.50.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in Calithera Biosciences by 36.5% in the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company’s stock worth $749,000 after acquiring an additional 496,100 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Calithera Biosciences in the first quarter worth $404,000. Affinity Asset Advisors LLC purchased a new position in Calithera Biosciences in the first quarter worth $404,000. Vanguard Group Inc. grew its position in Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock worth $415,000 after acquiring an additional 26,800 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 72,865 shares in the last quarter. 0.02% of the stock is currently owned by hedge funds and other institutional investors.
About Calithera Biosciences
Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.
- Five stocks we like better than Calithera Biosciences
- Where to Find Earnings Call Transcripts
- 5 best stocks to buy in a bear market
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 2 REIT stocks set to surge due to red hot data center demand
- The 3 Best Retail Stocks to Shop for in August
- How and when to use LEAPS stock options
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.